Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07169851 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
A Phase 2 study of Neoplasms and Nausea, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
- 20
- Study locations
NCT07169851 is a Phase 2 study of Neoplasms and Nausea that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 204 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT07169851, a Phase 2 study of Neoplasms and Nausea, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy. Participants who join this study will be in it until all parts are finished, which could take about 2 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3537021
- DRUG Standard of Care Antiemetic Therapies
- DRUG Background Chemotherapy
Study Locations (20)
California
- Marin Cancer Care - Greenbrae
- City of Hope Orange County Lennar Foundation Cancer Center - Irvine
- Cancer and Blood Specialty Clinic - Los Alamitos
- BASS Cancer Center - Walnut Creek
Florida
- Clavis Medical - Miami Lakes
- BRCR Global - Tamarac - Tamarac
North Carolina
- Oncology Specialists of Charlotte - Charlotte
- Southern Oncology Specialists - Huntersville
Texas
- World Research Link - Baytown
- John Peter Smith Hospital - Fort Worth
Other
- Ballarat Health Services - Ballarat Central
- Bendigo Health Care Group - Bendigo
Colorado
- UCHealth Harmony - Fort Collins
Georgia
- Summit Cancer Care, PC - Savannah
Illinois
- Hope and Healing Cancer Services - Hinsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2025-11-28 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07169851
The ClinicalTrials.gov registry entry for NCT07169851 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (87% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Neoplasms appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT07169851 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT07169851 about?
NCT07169851 is a clinical study titled "A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer". The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy. Participants who join this study will be in it until all parts are finished, which could take about 2 months.
What is the current status of trial NCT07169851?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2025-11-28. Estimated completion is 2026-09.
What conditions does trial NCT07169851 study?
This clinical trial studies the following conditions: Neoplasms, Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions.
What interventions are being tested in trial NCT07169851?
The interventions under investigation include: Placebo (DRUG), LY3537021 (DRUG), Standard of Care Antiemetic Therapies (DRUG), Background Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT07169851?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07169851 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
RECRUITING · Phase 2
-
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
RECRUITING · Phase 2
-
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
RECRUITING · Phase 2
-
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
RECRUITING · Phase 2
-
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.